Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Superior Tolerability Was Behind Pfizer/BioNTech’s Vaccine Switch

Far Fewer Suffered Fever Symptoms

Executive Summary

Pfizer and BioNTech made a last-minute switch to new lead candidate ahead of a pivotal Phase II/III trial, in which 11,000 volunteers have now already been dosed worldwide.

You may also be interested in...



Coronavirus Update: Human Vaccine Challenge Study Gains UK Backing

The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.

Executives On The Move: CEOs Named At Kaleido Biosciences, DewPoint Therapeutics And WntResearch AB

New chief business officer named at Ovoca Bio, and a new chairman at Opthea Ltd.

Coronavirus Update: No Mortality Gains From Remdesivir In WHO Trial, Gilead Questions Results

Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel